This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeCDC RecommendationAbout RSVAbout ABRYSVOAbout ABRYSVOStudy Design & Efficacy ProfileSafety ProfileDosing, Storage, ReconstitutionOrder ABRYSVOResourcesResourcesMaternal RSV Vaccine PlannerHealth Plan CoverageRequest A RepEventsMaterialsVideos
Prescribing InformationIndications AdultPatient Site
For eligible patients, ABRYSVO® is the first opportunity to help protect infants from RSV via maternal immunization1

Study Design

RSV-LRTD
Primary Endpoint

Hospitalizations
Secondary Endpoint

ABRYSVO was studied in a phase 3 clinical study: MATISSE1,3

MATISSE PHASE 3: POPULATION1

  • Maternal participants were randomized 1:1 to receive ABRYSVO (3711) or placebo (3709)
  • Pregnant women with high-risk pregnancies were excluded from the study

PATIENT CHARACTERISTICS AT BASELINE1

    • Demographic characteristics in regard to age, race, and ethnicity were balanced between ABRYSVO and placebo arms
    • Median pregnant woman's age at vaccination: 29 years
    • Median gestational age at vaccination was 31 weeks and 2 days (range 24-36.9 weeks)
       Trial dosing Interval1
      • Gestational age at vaccination: 24-36.9 weeks

         
      • Vaccine efficacy in the prevention of RSV-LRTD and severe RSV-LRTD within 3, 4, 5, and 6 months after birth*
       Approved dosing Interval1
      • Gestational age at vaccination: 32-36 weeks
         
      • Descriptive subgroup analysis in line with the indication, showing vaccine efficacy in prevention of RSV-LRTD and severe RSV-LRTD within 3 and 6 months after birth†
      RSV-associated lower respiratory tract disease (RSV-LRTD) defined in MATISSE1,4 ReferencesVaccine efficacy was defined as the relative risk reduction of severe RSV-LRTD and RSV-LRTD in infants born to pregnant women who received ABRYSVO compared to placebo.1This descriptive subgroup analysis was not controlled for multiple comparisons.1RSV-associated LRTD in infants was defined as a medically attended visit with a RT-PCR–confirmed RSV illness with 1 or more of the respiratory symptoms shown in this table.1In severe LRTD, tachypnea was defined as respiratory rate ≥70 breaths/minute (<age 2 months), ≥60 breaths/minute (age ≥2 to 12 months), or ≥50 breaths/minute (age ≥12 to 24 months). In LRTD, tachypnea was defined as respiratory rate ≥60 breaths/minute (age <2 months), ≥50 breaths/minute (age ≥2 to 12 months), or ≥40 breaths/minute (age ≥12 to 24 months).1Invasive or noninvasive.1ER=emergency room; ICU=intensive care unit; LRTD=lower respiratory tract disease; RSV=respiratory syncytial virus; RSV-LRTD=respiratory syncytial virus-associated lower respiratory tract disease; RT-PCR=reverse transcriptase-polymerase chain reaction; SpO2=oxygen saturation.
      ABRYSVO®: Powerful protection from RSV-LRTD during the most vulnerable months of an infant's life1The trial dosing interval included pregnant individuals vaccinated from gestational weeks 24 through 36.91Trial Dosing Interval Vaccine Efficacy (24-36.9-Week Gestational Period) (%)1 ReferencesThe prespecified success criterion (a CI lower bound >20%) was not met for this endpoint evaluation at 90 days.1This descriptive subgroup analysis included pregnant individuals vaccinated from gestational weeks 32 through 36 (in line with the approved dosing interval)1Approved Dosing Interval Vaccine Efficacy (32-36-Week Gestational Period) (%)1† ReferencesThis descriptive subgroup analysis was not controlled for multiple comparisons; results from 90 days and 180 days are presented.1CI=confidence interval; RSV=respiratory syncytial virus; RSV-LRTD=respiratory syncytial virus–associated lower respiratory tract disease.
      ABRYSVO helped protect infants from RSV-associated hospitalizations from birth through 6 months1*Trial Dosing Interval (24-36.9-Week Gestational Period) Vaccine Efficacy (%)  ReferencesSuccess criterion for the secondary endpoint was defined as having a CI lower bound >0.4

      CI=confidence interval; RSV=respiratory syncytial virus.
       Maternal RSV Vaccine Planner

      For eligible patients, this tool estimates the ABRYSVO vaccination window based upon estimated pregnancy due date, season, and location, consistent with the approved ABRYSVO indication and CDC recommendation.

       View the Planner Loading

      Stock ABRYSVO

      Make ABRYSVO available to your eligible patients by placing an order today.

       Order Now Loading       View Resources Discover helpful ABRYSVO resources, videos, and patient materials. Get Access Loading
      Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading
      Receive Updates About ABRYSVO Register NowLoading Request a Pfizer Sales Representative Connect Now Loading

      References:

      ABRYSVO (Respiratory Syncytial Virus Vaccine) Prescribing Information. Pfizer Inc; July 2025.Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus–associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices — United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122.Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16) (suppl appendix):1451-1464.

      To report an adverse event, please call 1-800-438-1985

      Pfizer for Professionals 1-800-505-4426

      This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

      © 2025 Pfizer Inc. All rights reserved.

      PP-A1G-USA-2565
      You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. 
      PP-MCL-USA-0367
      IndicationsABRYSVO is a vaccine indicated for:
      • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
      • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
      • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV

      Please click here for full Prescribing Information.
      Important Safety Information
      • Do not administer ABRYSVO to individuals with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of ABRYSVO
      • The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with ABRYSVO
      • A numerical imbalance in preterm births was observed compared to placebo in 2 clinical studies. Data are insufficient to establish or exclude a causal relationship between preterm birth and ABRYSVO. To avoid potential risk of preterm birth with use of ABRYSVO before 32 weeks of gestation, administer to pregnant individuals at 32 through 36 weeks gestational age
      • Appropriate medical treatment must be available in case of an anaphylactic reaction
      • Syncope (fainting) may occur with administration of injectable vaccines, including ABRYSVO. Procedures should be in place to avoid injury from fainting
      • Immunocompromised individuals, including those receiving immunosuppressive therapy, may have a diminished immune response to ABRYSVO
      • Vaccination with ABRYSVO may not protect all recipients
      • In clinical trials with adults aged 60+, the most commonly reported (≥10%) adverse reactions were fatigue (15.7%), headache (12.9%), pain at the injection site (10.6%), and muscle pain (10.2%)  
      • In clinical trials with adults aged 18-59, the most commonly reported (≥10%) adverse reactions were pain at the injection site (35.3%), muscle pain (24.4%), joint pain (12.4%), and nausea (11.8%)
      • In clinical trials with pregnant individuals, the most commonly reported (≥10%) adverse reactions were pain at the injection site (40.6%), headache (31.0%), muscle pain (26.5%), and nausea (20.0%)  
      • In clinical trials with infants born to pregnant individuals, low birth weight (5.1% ABRYSVO vs 4.3% placebo) and neonatal jaundice (7.3% ABRYSVO vs 6.9% placebo) were observed
      Individuals who received ABRYSVO during pregnancy are encouraged to contact 1-800-616-3791 to enroll in a Pregnancy Exposure Registry.

      Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

      Please see full Prescribing Information for ABRYSVO.       IndicationsABRYSVO is a vaccine indicated for:
      • active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older
         
      • active immunization of pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age
         
      • active immunization for the prevention of LRTD caused by RSV in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV
      You are now leaving PfizerProBy clicking Go to VaxAssist.com, you will be redirected to VaxAssist by Pfizer, where your patients can check eligibility and vaccine options. For additional information on ABRYSVO, please see Important Safety Information.